CGMs in GDM: Evolving Support
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “CGMs in GDM: Evolving Support” inside PodZeus.
This episode of Dr. Chapa’s OBGYN Clinical Pearls explores the rapidly evolving role of continuous glucose monitors (CGMs) in managing gestational diabetes mellitus (GDM), a field that has seen transformative advances from 2022 to 2026. While traditional management relies on four daily finger sticks—fasting and postprandial blood glucose checks—the podcast highlights a growing body of evidence supporting CGMs as a superior tool for improving maternal and neonatal outcomes. The host, Dr. Chapa, reviews key studies including a 2022 meta-analysis, the 2025 Steady Sugar Trial, Amy Valente’s 2025 RCT, and the 2026 GRACE trial, all showing significant benefits such as improved time-in-range (TIR), reduced birth weight, lower rates of LGA infants, fewer NICU admissions, and better glycemic control. Despite a 2026 DIP-GLUMO trial showing no significant clinical outcome differences, the overwhelming trend points to higher patient satisfaction and compliance with CGMs. The episode concludes with a call to embrace CGMs despite lingering gaps in optimal glucose targets and insurance coverage, emphasizing their potential to reduce patient burden and improve care quality. Key takeaways include: 1) CGMs significantly improve time-in-range and reduce adverse neonatal outcomes in GDM; 2) Patient preference and adherence are markedly higher with CGMs compared to traditional finger sticks; 3) The 2026 International Consensus Guidance now recognizes GDM as a key area for CGM use, though optimal targets remain under investigation; 4) Real-time data from CGMs enables proactive lifestyle and medication adjustments; 5) Despite cost and access barriers, CGMs represent a major step forward in personalized, patient-centered diabetes care during pregnancy.
CGMs significantly improve time-in-range and reduce adverse neonatal outcomes in gestational diabetes.
Patient satisfaction and adherence are much higher with CGMs compared to traditional finger-stick monitoring.
The 2026 International Consensus Guidance now supports CGM use in GDM, marking a major shift in clinical thinking.
Optimal glucose targets for GDM (e.g., TIR >90%, mean glucose <110 mg/dL) are emerging but still under study.
CGMs enable proactive management through real-time feedback, improving glycemic control and reducing complications.
The Evolution of Diabetes Care: From Water Tasters to CGMs
“Ah, that's so sweet! Now, now that we've covered that nonsense, back on track.”
The Data Gap: CGMs in GDM vs. Type 1 and Type 2 Diabetes
The episode clarifies that while the strongest evidence for CGM use exists in type 1 and type 2 diabetes during pregnancy, the data for gestational diabetes (GDM) has historically been limited. Dr. Chapa outlines the standard of care—four daily finger sticks—and critiques its burden on patients. He introduces the central question: can CGMs deliver meaningful outcomes in GDM, and is the evidence strong enough to shift practice?
Rapid Fire: Key Studies from 2022 to 2026
“CGM group had significantly lower unscheduled c-section rates. That's good. They had lower preterm deliveries and neonates had lower rates of being LGA as well as lower rates of NICU admissions.”
The Counterpoint: DIP-GLUMO Trial and Clinical Reality
“Individuals expressed a higher preference for the real-time continuous glucose monitor. And so, this finding suggests that these monitors could be offered to simplify the management of gestational diabetes.”
The Road Ahead: Gaps, Guidelines, and Future Directions
“We can't ignore the value of continuous glucose monitors here. Podcast family, as I thought this was interesting because we've had these recent developments from February 2026. I had somebody who messaged me through our social media channels asking about CGMs for pregnancy and or for GDM. And I'm like, hey, even though we have some gaps, I am a believer in this.”
“CGM group had significantly lower unscheduled c-section rates. That's good. They had lower preterm deliveries and neonates had lower rates of being LGA as well as lower rates of NICU admissions.”
“We can't ignore the value of continuous glucose monitors here. Podcast family, as I thought this was interesting because we've had these recent developments from February 2026.”
“Ah, that's so sweet! Now, now that we've covered that nonsense, back on track.”
Host
Guest
Dr. Chapa
person
Amy Valente
person
2026 International Consensus Guidance
other
Water Tasters
other
SMFM
organization
Diabetes Care
other
Dexcom G6
product
Steady Sugar Trial
other
The Lancet
other
Lancet Diabetes & Endocrinology
other
OPS vs RRS: April 2026 AJOG
Dr. Chapa’s OBGYN Clinical Pearls • 23m • 4/1/2026
Exploring Encompass RNA PreE (At-Home) Test
Dr. Chapa’s OBGYN Clinical Pearls • 19m • 4/4/2026
Livi Post-Sex Vaginal Device: Hmmmm
Dr. Chapa’s OBGYN Clinical Pearls • 11m • 4/9/2026
Fetal AC> 90%: Diagnosis?
Dr. Chapa’s OBGYN Clinical Pearls • 14m • 4/11/2026
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “CGMs in GDM: Evolving Support” inside PodZeus.
Start discovering podcast insights today
Start with a 7-day trial and explore a growing catalog of popular podcasts. No credit card required.
No credit card required • 7-day trial • Cancel anytime